Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
20 hedge funds and large institutions have $306K invested in Statera Biopharma, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
46% more capital inflows, than outflows
Capital inflows: $78K | Capital outflows: $53.6K
1.2% less ownership
Funds ownership: 3.12% → 1.92% (-1.2%)
5% less funds holding
Funds holding: 21 → 20 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35.1K |
| 2 |
Virtu KCG Holdings
New York
|
+$22.5K |
| 3 |
Renaissance Technologies
New York
|
+$18.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.56K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$52K |
| 2 |
Tower Research Capital (TRC)
New York
|
-$1K |
| 3 |
Morgan Stanley
New York
|
-$316 |
| 4 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$257 |
STAB Hedge Fund Activity: Q4 2016 in Review
20 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2016, worth a combined $306K — down 10% from $341K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of STAB and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $35.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $52K sold.
- 20 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2016, down from 21 in Q3 2016.
- Funds reported $306K of Statera Biopharma, Inc. Common Stock stock for Q4 2016, down 10% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2016 and 3 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2016 was Susquehanna International Group, an estimated $35.1K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2016 was Citadel Advisors, an estimated $52K sold.
Based on aggregated 13F filings for Q4 2016.